[The psychopharmacology of the comorbid disorders associated with attention deficit hyperactivity disorder].
BACKGROUND
The pharmacological treatment most commonly used in attention deficit hyperactivity disorder (ADHD) has traditionally consisted in the administration of psychostimulants. The particular association with comorbid disorders makes it essential to utilise different therapeutic approaches and this accounts for the growing therapeutic arsenal currently available for use in this condition.


METHODS
It is important to be familiar with the different comorbidities because they are especially frequent and also because of their effect on the prognosis. Thus, it is necessary to reach a good diagnosis as early as possible in order to implement a therapy that allows the problem to be curbed. To do so, we need to know about the different pharmaceuticals that have to some extent or other proved to be effective.


CONCLUSIONS
This paper aims to offer a global view of the problem by analysing the characteristics of the comorbid disorders associated with ADHD and the pharmacological tools that enable us to modify their deleterious effects.
de la Osa-Langreo
A
A
Hospital Infantil La Fe, 46009 Valencia, Espana.
Mulas
F
F
Téllez de Meneses
M
M
Gandía
R
R
Mattos
L
L
D000293:Adolescent; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000453:epidemiology*; D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D015897:Comorbidity; D039721:Diagnostic and Statistical Manual of Mental Disorders; D005260:Female; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000453:epidemiology*
D000697:Central Nervous System Stimulants